Choriogonadotropin alfa
As of the edition of 20 October 2026, Choriogonadotropin alfa is a protein: marketed, first approved in 2000 (US); acts on LHCGR; US protection ended in 2012.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Protein
- Brand name
- Ovidrel
- First approved
- 20 September 2000 (US)
- Approvals on record
- 6 in 3 regions
- Holder of the most recent approval
- Merck KGaA; 3 holders in all
- Registered trials
- 39, 7 stopped early
- Disease areas
- Urinary and reproductive; Pregnancy and women's health; Cancer; Hormones; Nutrition and metabolism; Inherited and neonatal
US protection
US protection ended in 2012.
US protection ended in 2012, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Merck KGaA. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| LHCGR | Lutropin-choriogonadotropic hormone receptor | P22888 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 13 | 6 | 1 | 1 |
| Phase 1 | 4 | 1 | 1 | 1 |
| Phase 2 | 5 | 2 | 0 | 3 |
| Phase 3 | 10 | 5 | 2 | 1 |
| Phase 4 | 7 | 4 | 1 | 1 |
| All trials | 39 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Originator, Applicant and Lead sponsor of trials | 2000 to now |